Therefore, therapeutically increasing RAC1B expression in poorly differentiated cancer cells from PDAC or TNBC may be a promising strategy to block the tumor-promoting functions of TGFβ1 and eventually enhance their redifferentiation to the less malignant epithelial phenotype. Here, TGFB1 is linked to cancer.